Skip to main content

4 Result(s)

within I. Iacona Remove this filter

and

  1. No Access

    Article

    A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma

    We studied a model of in vivo purging with Rituximab and high-dose (HD) cytarabine in 14 patients with relapsed/refractory follicular lymphoma and two with refractory mantle cell lymphoma enrolled in a program of...

    L Arcaini, E Orlandi, E P Alessandrino, I Iacona… in Bone Marrow Transplantation (2004)

  2. No Access

    Article

    Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling

    Objective: This study investigated the pharmacokinetics of tretinoin during alternating cycles of 1 week of tretinoin treatment and 1 week drug-free in patients with Ph1+ chronic myelogenous leuk...

    Dr Mario B. Regazzi, D. Russo, I. Iacona, S. Sacchi… in Clinical Drug Investigation (1998)

  3. No Access

    Article

    All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase

    Since in vitro observations indicated that all-trans retinoic acid (ATRA), especially in combination with IFNα, can exert significant suppressive effects on Ph+ cells, we investigated the effects and the pharmaco...

    D Russo, M Regazzi, S Sacchi, G Visani, M Lazzarino, G Avvisati, PG Pelicci… in Leukemia (1998)

  4. No Access

    Article

    Abstracts of posters

    L. Suffisseau, M. C. Taugourdeau, F. W. Goldstein… in Pharmacy World and Science (1994)